Feigin, A., Evans, E. E., Fisher, T. L., Leonard, J. E., Smith, E. S., Reader, A., … Huntington Study Group SIGNAL investigators, . (2024). Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial. Nat Med, 30(2), 606. https://doi.org/10.1038/s41591-022-02070-0

Feigin, Andrew, Elizabeth E. Evans, Terrence L. Fisher, John E. Leonard, Ernest S. Smith, Alisha Reader, Vikas Mishra, et al. “Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.” Nat Med 30, no. 2 (February 2024): 606. https://doi.org/10.1038/s41591-022-02070-0.

Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, et al. Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial. Nat Med. 2024 Feb;30(2):606.

Feigin, Andrew, et al. “Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.” Nat Med, vol. 30, no. 2, Feb. 2024, p. 606. Pubmed, doi:10.1038/s41591-022-02070-0.

Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M, Huntington Study Group SIGNAL investigators. Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial. Nat Med. 2024 Feb;30(2):606.